To validate the critical role of CaSR in pathological new bone formation, a selective CaSR antagonist, NPS‐2143, which binds to the seven transmembrane domains and disrupts G protein‐mediated downstream signalling, was systemically administrated during the pathologic process of ankylosis in these animal models (Hannan et al, 2018b). Here, CASR is linked to ankylosis.